Patent ID: 6451803
Filing Date: 2002-09-17
Classification: A61P,C07D

Abstract:
A method for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal, comprising administering to said mammal requiring such treatment or prevention:a) a 5-HT1A antagonist or a pharmaceutically acceptable salt thereof; and b) a 5-HT1D antagonist of formula I â€ƒor a pharmaceutically acceptable salt thereof, wherein R1 is a group of the formula G1, G2, G3, G4, G5 or G6 depicted below: â€ƒwherein the broken line indicates an optional double bond; a is zero to eight; m is 0, 1, 2, 3 or 4; p is 1, 2 or 3; D is oxygen, sulfur, SO, SO2, or NR7; E is oxygen, sulfur, SO or SO2; X is hydrogen, chloro, fluoro, bromo, iodo, cyano, (C1-C6)alkyl, hydroxy, trifluoromethyl, (C1-C6)alkoxy, â€”S(O)t(C1-C6)alkyl wherein t is 0, 1 or 2, â€”CO2R10 or â€”CONR11R12; R2 is â€”(CH2)tB, wherein t is 0, 1, 2 or 3, and B is hydrogen, phenyl, naphthyl or a 5 or 6 membered heteroaryl group containing from one to four heteroatoms in the ring, and wherein each of the foregoing phenyl, naphthyl and heteroaryl groups may optionally be substituted with one or more substituents independently selected from chloro, fluoro, bromo, iodo, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C6)alkyl-, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, â€”COOH and â€”SOn(C1-C6)alkyl wherein n is 0, 1 or 2; R3 and R4 are each independently hydrogen, (C1-C4alkyl or â€”(CH2)qâ€”J wherein q is 0, 1, 2 or 3, and J is phenyl or naphthyl, wherein said phenyl or naphthyl may be optionally substituted with one to three substituents independently selected from the group consisting of chloro, fluoro, bromo, iodo, (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethyl, cyano and â€”S(O)k(C1-C6)alkyl wherein k is 0, 1 or 2; R5 is hydrogen or (C1-C3)alkyl; R6 is selected from the group consisting of hydrogen, (C1-C6)alkyl optionally substituted with (C1-C6)alkoxy or one to three fluorine atoms, or [(C1-C4)alkyl]aryl wherein the aryl moiety is phenyl, naphthyl, or heteroaryl-(CH2)qâ€”, wherein the heteroaryl moiety is selected from the group consisting of pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl and benzisothiazolyl and q is zero, one, two, three or four, and wherein said aryl and heteroaryl moieties may optionally be substituted with one or more substituents independently selected from the group consisting of chloro, fluoro, bromo, iodo, (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethyl, cyano and â€”SOg(C1-C6)alkyl, wherein g is zero, one or two; R7 is selected from the group consisting of hydrogen, (C1-C6)alkyl, [(C1-C4)alkyl]aryl wherein the aryl moiety is phenyl, naphthyl, or heteroaryl-(CH2)râ€”, wherein the heteroaryl moiety is selected from the group consisting of pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl and benzisothiazolyl and r is zero, one, two, three or four, and wherein said aryl and heteroaryl moieties may optionally be substituted with one or more substituents independently selected from the group consisting of chloro, fluoro, bromo, iodo, (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethyl, â€”C(&boxH;O)â€”(C1-C6)alkyl, cyano and â€”SOj(C1-C6)alkyl, wherein j is zero, one or two; or R6 and R7 taken together form a 2 to 4 carbon chain; R8 is hydrogen or (C1-C3)alkyl; R9 is hydrogen or (C1-C6)alkyl; or R6 and R9, together with the nitrogen atom to which they are attached, form a 5 to 7 membered heteroalkyl ring that may contain from zero to four heteroatoms selected from nitrogen, sulfur and oxygen; each of R10, R11 and R12 is selected, independently, from the radicals set forth in the definition of R3; or R11 and R12, together with the nitrogen to which they are attached, form a 5 to 7 membered heteroalkyl ring that may contain from zero to four heteroatoms selected from nitrogen, sulfur and oxygen; and each R13 is, independently, (C1-C4)alkyl or a (C1-C4)methylene bridge from one of the ring carbons of the piperazine or piperidine ring of G1 or G2, respectively, to the same or another ring carbon or a ring nitrogen of the piperazine or piperidine ring of G1 or G2, respectively, having an available bonding site, or to a ring carbon of R6 having an available bonding site; with the proviso that when B is hydrogen, t is not zero; and with the proviso that when the broken line in formula G2 is a double bond, R8 is absent; wherein the amounts of the active compounds are such that the combination is effective in treating or preventing such disorder or condition.